ReViral
Seedtable Score
52
Startups
1
Funding Rounds
2
Investors
$44m
Money raised
Overview
ReViral, based in London, offers a strong business opportunity in antiviral treatments. As a biotech firm, it focuses on innovative antiviral solutions to address the ongoing issue of viral infections. By targeting health tech and pharma sectors, ReViral aims to develop cutting-edge treatments that could reduce morbidity and mortality rates. Operating on a B2B model, the company collaborates with other businesses rather than selling directly to consumers. With backing from investors like Novo A/S and Andera Partners, ReViral is well-positioned to advance its research and bring new antiviral treatments to market. Its commitment to innovation sets it apart from existing antiviral medications and vaccines.
- Website: https://reviral.co.uk
- Business model: b2b
- Company size: 11 - 51 employees
- Headquarters: London, UK
- Founded: 2011
- Social accounts: Twitter Linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Investors (2)
Funding
Funding series
Funding Series Analysis
The company ReViral has raised a total of $44m in funding over 1 rounds.
Key Insights:
- Series C: $44m
ReViral Series C (2020, $44M)
$44m